Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide)

Overview

Enteric-coated oral capsule blend of palmitoylethanolamide (PEA), BPC-157 arginate, KPV, and N-acetyl larazotide, marketed for gut-barrier / GI support. A vendor-formulated combination; not clinically validated as a blend. Evidence is component-level only.

Mechanism of Action

Component-level rationale only: PEA (a fatty-acid amide) for anti-inflammatory / PPAR-α signaling; BPC-157 for mucosal-repair signaling in rodents; KPV (an α-MSH fragment) for anti-inflammatory activity; N-acetyl larazotide (a zonulin antagonist) for tight-junction / intestinal-permeability modulation. Synergy in humans is unproven.

Research Summary

Vendor-created oral formulation; no human trial of the four-way combination has been published. Larazotide has the most individual clinical study (celiac-related intestinal permeability); the others are predominantly preclinical for GI use.

Reported Side Effects

• See individual compound profiles for PEA, BPC-157, KPV, and larazotide

Frequently asked questions

Has Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide) been independently lab-tested?

Disclosed Labs has collected 1 Certificate of Analysis (COA) for Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide) from 1 independent testing lab. 1 vendor has submitted material for testing. Full testing data is available at https://www.disclosedlabs.com/peptides/gut-matrix/testing.

Which labs have tested Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide)?

Independent labs that have tested Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide) include: Ethos Analytics (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

How does Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide) work?

Component-level rationale only: PEA (a fatty-acid amide) for anti-inflammatory / PPAR-α signaling; BPC-157 for mucosal-repair signaling in rodents; KPV (an α-MSH fragment) for anti-inflammatory activity; N-acetyl larazotide (a zonulin antagonist) for tight-junction / intestinal-permeability modulation. Synergy in humans is unproven.

What does the research say about Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide)?

Vendor-created oral formulation; no human trial of the four-way combination has been published. Larazotide has the most individual clinical study (celiac-related intestinal permeability); the others are predominantly preclinical for GI use.